National Cancer Institute - U.S. National Institutes of Health - www.cancer.gov
National Cancer Institute - U.S. National Institutes of Health - www.cancer.gov

Clinical Trials by Cancer Site

Pediatric Cancers

Pediatric cancers are rare, yet it is estimated that in 2008 there will be 10,730 children from birth to age 14 who are newly diagnosed with the disease. Some of the most common childhood cancers are: leukemia, brain and other central nervous system (CNS) tumors, Wilms' tumor (kidney cancer), lymphoma (Hodgkin's and Non-Hodgkin's), rhabdomyosarcoma (soft tissue sarcoma), retinoblastoma (ocular cancer), osteosarcoma, and Edwin's sarcoma. The causes of childhood cancers are unknown and common links are difficult to determine because all types of childhood cancers develop differently based on the patient's age, race, gender, and other factors.

Treatment options for pediatric cancers may vary depending on the patient's age, type of cancer, stage of the disease, and other medical conditions, and should be discussed with the patient's physician.

Pediatric Cancer Clinical Trials

The Center for Cancer Research (CCR), NCI's largest division doing research on campus, conducts pediatric cancer clinical trials at the NIH Clinical Center in Bethesda, Md. NCI accepts referrals to pediatric cancer clinical trials conducted in Bethesda, Md., through its Clinical Trials Referral Office (formerly the Clinical Studies Support Center) at 1-888-NCI-1937 (1-888-624-1937).

NCI is currently conducting the following trials for pediatric cancer patients. Click on the trials below for additional details, including a summary of eligibility criteria, treatment plan, and information on how to contact the principal investigators and their staff directly.


  
Trial and Protocol Number
Pediatric Cancers
Phase II
Phase II Study of Sequential Gemcitabine and Docetaxel in Patients With Recurrent Osteosarcoma or Ewing’s Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
NCI-04-C-0001

Principal Investigator:Referral Contact:
Elizabeth FoxPediatric Oncology
301-402-66411-877-624-4878
(Toll free)

Phase I
A Phase I Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor BAY 43-9006 (Sorafenib) in Children With Refractory Solid Tumors or Refractory Leukemias
NCI-06-C-0233

Principal Investigator:Referral Contact:
Brigitte WidemannPediatric Oncology
301-496-73871-877-624-4878
(Toll free)

Phase I Trial of Cediranib (AZ2171), an Orally Bioavailable Antiangiogenic Agent, in Children and Adolescents With Refractory or Recurrent Solid Tumors or Acute Myelogenous Leukemia
NCI-06-C-0152

Principal Investigator:Referral Contact:
Elizabeth FoxPediatric Oncology
301-402-66411-877-624-4878
(Toll free)

No Phase
A Pilot Study of Tumor Vaccination in Patients With Neuroblastoma and Pediatric Sarcomas and Altered T-Cell Homeostasis
NCI-07-C-0206

Principal Investigator:Referral Contact:
Crystal MackallPediatric Oncology
301-402-59401-877-624-4878
(Toll free)



  
Trial and Protocol Number
AIDS Related Cancers
Phase II
Short-Course EPOCH-Rituximab in Untreated CD-20+ HIV-Associated Lymphomas
NCI-01-C-0030

Principal Investigator:Referral Contact:
Wyndham H. WilsonNicole Grant
301-435-2415301-594-2947
grantn@mail.nih.gov
Phase I
Pilot Study of Antiretroviral Therapy With or Without Bortezomib or Combination Chemotherapy and Rituximab or Observation Only in Treating Patients With Castleman’s Disease
NCI-04-C-0275

Principal Investigator:Referral Contact:
Robert YarchoanKaren Aleman
301-496-8959301-496-8959
1-800-243-2732 ext. 4 (Toll Free)
alemank@mail.nih.gov


  
Trial and Protocol Number
Brain Tumor
No Phase
Comparative Trial of Pediatric CNS Tumor Activity as Assessed by PET Imaging and Proton Magnetic Resonance Spectroscopy Imaging (MRSI)
NCI-03-C-0278

Principal Investigator:Referral Contact:
Katherine E. WarrenRobyn Bent
301-496-4256301-496-8009
rbent@mail.nih.gov


  
Trial and Protocol Number
Brain Tumor (Childhood)
Phase II
Phase II Study of Pegylated Interferon Alfa-2b (PEG-Intron) in Children With Diffuse Pontine Gliomas
NCI-02-C-0193

Principal Investigator:Referral Contact:
Katherine E. WarrenRobyn Bent
301-496-4256301-496-8009
rbent@mail.nih.gov
No Phase
An Exploratory Study of Biologic and Pathophysiologic Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors
NCI-06-C-0219

Principal Investigator:Referral Contact:
Katherine E. WarrenRobyn Bent
301-496-4256301-496-8009
rbent@mail.nih.gov


  
Trial and Protocol Number
Graft-Versus-Host Disease
Pilot
A Pilot Study of Imatinib Mesylate in Children and Adults With Sclerotic Skin Changes of Chronic Graft-Versus-Host Disease
NCI-08-C-0148

Principal Investigator:Referral Contact:
Edward CowenSusan Booher
301-496-4299301-402-1474
boohers@mail.nih.gov


  
Trial and Protocol Number
Hematologic/Blood Cancers
Phase I/II
A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies
NCI-08-C-0051

Principal Investigator:Referral Contact:
Alan WaynePediatric Oncology
301-496-42561-877-624-4878
(Toll free)

Pilot Study of Non-Myeloablative, HLA-matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
NCI-01-C-0125

Principal Investigator:Referral Contact:
Alan WaynePediatric Oncology
301-496-42561-877-624-4878
(Toll free)

Phase I
A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents, and Young Adults With Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin’s Lymphoma (NHL)
NCI-08-C-0123

Principal Investigator:Referral Contact:
Alan WaynePediatric Oncology
301-496-42561-877-624-4878
(Toll free)

Pediatric Phase I Trial of BL22 for Refractory CD22-Positive Leukemias and Lymphomas
NCI-04-C-0079

Principal Investigator:Referral Contact:
Alan WaynePediatric Oncology
301-496-42561-877-624-4878
(Toll free)



  
Trial and Protocol Number
Leukemia
Phase I/II
Phase I/II Study of the Efficacy and Toxicity of Humanized Anti-Tac (Zenapax®) in the Therapy of Tac-Expressing Adult T-Cell Leukemia
NCI-00-C-0030

Principal Investigator:Referral Contact:
John C. MorrisSuzanne Fioravanti
301-402-2912301-594-6544
fioravas@mail.nih.gov


  
Trial and Protocol Number
Leukemia (Childhood)
Phase I
Phase I Trial and Pharmacokinetic Study of BMS-247550 (NSC 710428, Ixabepilone), an Epothilone B Analog, in Pediatric Patients with Refractory Solid Tumors and Leukemias
NCI-02-C-0031

Principal Investigator:Referral Contact:
Brigitte WidemannPediatric Oncology
301-496-73871-877-624-4878
(Toll free)



  
Trial and Protocol Number
Lymphoma
Phase II
Phase II Study of UCN-01 in Relapsed or Refractory Systemic Anaplastic Large Cell and Mature T-Cell Lymphomas
NCI-04-C-0173

Principal Investigator:Referral Contact:
Wyndham H. WilsonPeggy Shovlin
301-435-2415301-594-6597
mshovlin@mail.nih.gov


  
Trial and Protocol Number
Malignant Peripheral Nerve Sheath Tumor
Phase II
Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Unresectable Malignant Peripheral Nerve Sheath Tumors
NCI-06-C-0043

Principal Investigator:Referral Contact:
Brigitte WidemannPediatric Oncology
301-496-73871-877-624-4878
(Toll free)



  
Trial and Protocol Number
Neuroblastoma
Phase II
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
NCI-07-C-0074

Principal Investigator:Referral Contact:
Elizabeth FoxPediatric Oncology
301-402-66411-877-624-4878
(Toll free)



  
Trial and Protocol Number
Neurofibroma/Neurofibromatosis
Phase II
A Phase II Trial of Peginterferon Alpha-2b (Pegintron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic, or Life-Threatening Plexiform Neurofibromas
NCI-08-C-0130

Principal Investigator:Referral Contact:
Brigitte WidemannPediatric Oncology
301-496-73871-877-624-4878
(Toll free)

A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type I Related Plexiform Neurofibromas
NCI-08-C-0096

Principal Investigator:Referral Contact:
Brigitte WidemannPediatric Oncology
301-496-73871-877-624-4878
(Toll free)

Phase I
Phase I Trial of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, Nexavar®) in Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas
NCI-08-C-0180

Principal Investigator:Referral Contact:
Brigitte WidemannPediatric Oncology
301-496-73871-877-624-4878
(Toll free)



  
Trial and Protocol Number
Sarcoma
Phase II
SARC Global Collaboration: A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Patients With Recurrent or Refractory Ewing’s Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas
NCI-08-C-0080

Principal Investigator:Referral Contact:
Lee HelmanPediatric Oncology
301-496-42571-877-624-4878
(Toll free)

Phase I
Pilot Study of Allogeneic/Syngeneic Blood Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
NCI-02-C-0259

Principal Investigator:Referral Contact:
Terry FryPediatric Oncology
301-402-12981-877-624-4878
(Toll free)



  
Trial and Protocol Number
Solid Tumor (Childhood)
Phase I
A Phase I Study of VEGF Trap (NSC #724770, IND #100137) in Children With Refractory Solid Tumors (Children’s Oncology Group Study ADVL0714)
NCI-08-C-0179

Principal Investigator:Referral Contact:
Elizabeth FoxPediatric Oncology
301-402-66411-877-624-4878
(Toll free)

Multiple Ascending Dose (MAD) Phase I Study of the IGF-1R Antagonist R1507 Administered as an Intravenous Infusion in Children and Adolescents With Advanced Solid Tumors
NCI-08-C-0010

Principal Investigator:Referral Contact:
Frank BalisPediatric Oncology
301-496-00851-877-624-4878
(Toll free)

A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Adults With Treatment Refractory Cancer
NCI-08-C-0007

Principal Investigator:Referral Contact:
Crystal MackallPediatric Oncology
301-402-59401-877-624-4878
(Toll free)

A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children With Refractory Solid Tumors
NCI-07-C-0220 (A Cooperative Group Study: ADVL0612)

Principal Investigator:Referral Contact:
Elizabeth FoxPediatric Oncology
301-402-66411-877-624-4878
(Toll free)

A Phase I Study of BMS-354825 (Dasatinib) in Children With Recurrent/Refractory Solid Tumors or Imatinib Resistant Ph+ Leukemia (A Cooperative Group Study)
NCI-07-C-0166

Principal Investigator:Referral Contact:
Elizabeth FoxPediatric Oncology
301-402-66411-877-624-4878
(Toll free)

A Phase I Trial and Pharmacokinetic Study of Trabectedin (YONDELIS®, ET-743) in Children and Adolescents With Relapsed or Refractory Solid Tumors
NCI-07-C-0054

Principal Investigator:Referral Contact:
Elizabeth FoxPediatric Oncology
301-402-66411-877-624-4878
(Toll free)

Phase I Trial of Monoclonal Antibody HGS-ETR2 (Lexatumumab) in Patients With Refractory Pediatric Solid Tumors
NCI-07-C-0040

Principal Investigator:Referral Contact:
Crystal MackallPediatric Oncology
301-402-59401-877-624-4878
(Toll free)



  
Trial and Protocol Number
Thyroid Cancer (Childhood)
Phase I/II
Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Cancer
NCI-07-C-0189

Principal Investigator:Referral Contact:
Frank BalisPediatric Oncology
301-496-00851-877-624-4878
(Toll free)



  
Trial and Protocol Number
Xeroderma Pigmentosum
No Phase
Cancer Risk in Xeroderma Pigmentosum Heterozygotes
NCI-02-C-0313

Principal Investigator:Referral Contact:
Kenneth H. KraemerDeborah Tamura
301-496-9033301-594-5030
tamurad@mail.nih.gov


Back to Top
Health and Human Services National Institutes of Health National Cancer Institute USA.gov National Cancer Institute Clinical Trials at NIH - Be part of the cure